Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome
WO2021081244A1
Base editor-mediated cd33 reduction to selectively protect therapeutic cells
WO2021072127A2
Engineered trimeric cd70 proteins and uses thereof
US2021085716A1
Antigen binding molecules for small cell lung cancer
WO2021055372A1
Chimeric receptor proteins and uses thereof
WO2021034976A1
T-cell immunotherapy specific for wt-1
WO2021021825A1
Methods and compositions for inducing notch signaling in tumor microenvironments
WO2021016422A1
Methods and compositions for treating androgen receptor deficient, androgen receptor low, and castration-resistant prostate cancers
US2021010067A1
Kits and methods for assessing a condition or a risk of developing a condition, and related methods of treatment
WO2021003432A1
Recombinant ad35 vectors and related gene therapy improvements
WO2021003413A2
Self-assembling circular tandem repeat proteins with increased stability
WO2020264177A1
Methods and compositions comprising brd9 activating therapies for treating cancers and related disorders
WO2020257648A1
Microlumenal targeting of cancer cells
US2020393465A1
Markers, methods and systems for identifying cell populations, diagnosing, monitoring, predicting and treating conditions
WO2020198154A1
Proactive monitoring of patient reported outcomes to reduce emergency and inpatient care
WO2020191359A1
Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor
WO2020191060A2
Circumsporozoite proteins with increased expression in mammalian cells
WO2020185796A1
High avidity wt1 t cell receptors and uses thereof
WO2020180700A1
Protein residue mapping using a combination of deep mutational scanning and phage display high throughput sequencing
WO2020176790A1
Hydrogel compositions and methods for treatment of malignancies
